|
1
|
Althuis MD, Dozier JM, Anderson WF, Devesa
SS and Brinton LA: Global trends in breast cancer incidence and
mortality 1973–1997. Int J Epidemiol. 34:405–412. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Forbes JF: The incidence of breast cancer:
the global burden, public health considerations. Semin Oncol.
24(Suppl 1): S1–20–S1–35. 1997.
|
|
4
|
Rakha EA, El-Sayed ME, Green AR, Lee AH,
Robertson JF and Ellis IO: Prognostic markers in triple-negative
breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar
|
|
5
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hudis CA and Gianni L: Triple-negative
breast cancer: an unmet medical need. Oncologist. 16(Suppl 1):
1–11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kaelin WG Jr and Ratcliffe PJ: Oxygen
sensing by metazoans: the central role of the HIF hydroxylase
pathway. Mol Cell. 30:393–402. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhong H, De Marzo AM, Laughner E, Lim M,
Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons
JW: Overexpression of hypoxia-inducible factor 1alpha in common
human cancers and their metastases. Cancer Res. 59:5830–5835.
1999.PubMed/NCBI
|
|
10
|
Sun HC, Qiu ZJ, Liu J, Sun J, Jiang T,
Huang KJ, Yao M and Huang C: Expression of hypoxia-inducible
factor-1α and associated proteins in pancreatic ductal
adenocarcinoma and their impact on prognosis. Int J Oncol.
30:1359–1367. 2007.PubMed/NCBI
|
|
11
|
Rasheed S, Harris AL, Tekkis PP, Turley H,
Silver A, McDonald PJ, Talbot IC, Glynne-Jones R, Northover JM and
Guenther T: Hypoxia-inducible factor-1alpha and -2alpha are
expressed in most rectal cancers but only hypoxia-inducible
factor-1alpha is associated with prognosis. Br J Cancer.
100:1666–1673. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Conley SJ, Gheordunescu E, Kakarala P,
Newman B, Korkaya H, Heath AN, Clouthier SG and Wicha MS:
Antiangiogenic agents increase breast cancer stem cells via the
generation of tumor hypoxia. Proc Natl Acad Sci uSA. 109:2784–2789.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Papandreou I, Cairns RA, Fontana L, Lim AL
and Denko NC: HIF-1 mediates adaptation to hypoxia by actively
downregulating mitochondrial oxygen consumption. Cell Metab.
3:187–197. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mikstacka R, Stefański T and Różański J:
Tubulin-interactive stilbene derivatives as anticancer agents. Cell
Mol Biol Lett. 18:368–397. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cai YC, Zou Y, Ye YL, Sun HY, Su QG, Wang
ZX, Zeng ZL and Xian LJ: Anti-tumor activity and mechanisms of a
novel vascular disrupting agent,
(Z)-3,4′,5-trimethoxylstilbene-3′-O-phosphate disodium (M410).
Invest New Drugs. 29:300–311. 2011. View Article : Google Scholar
|
|
16
|
Wilson WR and Hay MP: Targeting hypoxia in
cancer therapy. Nat Rev Cancer. 11:393–410. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vaupel P, Mayer A and Höckel M: Tumor
hypoxia and malignant progression. Methods Enzymol. 381:335–354.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gong L, Zhang W, Zhou J, Lu J, Xiong H,
Shi X and Chen J: Prognostic value of HIFs expression in head and
neck cancer: a systematic review. PLoS One. 8:e750942013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Semenza GL: Defining the role of
hypoxia-inducible factor 1 in cancer biology and therapeutics.
Oncogene. 29:625–634. 2010. View Article : Google Scholar :
|
|
20
|
van der Groep P, Bouter A, Menko FH, van
der Wall E and van Diest PJ: High frequency of HIF-1alpha
overexpression in BRCA1 related breast cancer. Breast Cancer Res
Treat. 111:475–480. 2008. View Article : Google Scholar
|
|
21
|
Bos R, van der Groep P, Greijer AE,
Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ and van
der Wall E: Levels of hypoxia-inducible factor-1α independently
predict prognosis in patients with lymph node negative breast
carcinoma. Cancer. 97:1573–1581. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schindl M, Schoppmann SF, Samonigg H,
Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P
and Oberhuber G; Austrian Breast and Colorectal Cancer Study Group:
Overexpression of hypoxia-inducible factor 1α is associated with an
unfavorable prognosis in lymph node-positive breast cancer. Clin
Cancer Res. 8:1831–1837. 2002.PubMed/NCBI
|
|
23
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Welsh S, Williams R, Kirkpatrick L,
Paine-Murrieta G and Powis G: Antitumor activity and
pharmacodynamic properties of PX-478, an inhibitor of
hypoxia-inducible factor-1alpha. Mol Cancer Ther. 3:233–244.
2004.PubMed/NCBI
|
|
25
|
Kong D, Park EJ, Stephen AG, Calvani M,
Cardellina JH, Monks A, Fisher RJ, Shoemaker RH and Melillo G:
Echi-nomycin, a small-molecule inhibitor of hypoxia-inducible
factor-1 DNA-binding activity. Cancer Res. 65:9047–9055. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim KH, Jung HJ and Kwon HJ: A new
anti-angiogenic small molecule, G0811, inhibits angiogenesis via
targeting hypoxia inducible factor (HIF)-1α signal transduction.
Biochem Biophys Res Commun. 441:399–404. 2013. View Article : Google Scholar : PubMed/NCBI
|
